Background: Lactitol (4-beta-D: -galactopyranosyl-D: -glucitol) is a sugar alcohol used as a sweetener. Previous studies have shown that it has a beneficial effect on intestinal microflora.
Aims Of The Study: To determine whether low doses of lactitol had beneficial effects without eliciting adverse gastrointestinal symptoms.
Methods: Faecal bacterial populations (total anaerobes, total aerobes, enterobacteria, bifidobacteria and lactobacilli), faecal pH and faecal short chain fatty acids (SCFA) were studied in a randomized longitudinal study of 75 non-adapted healthy adults before and after consumption of low doses of lactitol. Subjects consumed 25 g tablets of milk chocolate containing 10 g sweetener as sucrose:lactitol in ratios of 10:0, 5:5 or 0:10 daily for 7 d.
Results: No significant changes in faecal bacterial counts occurred in the 10:0 or 5:5 sucrose:lactitol groups. There were no significant changes in faecal anaerobes, aerobes, Enterobacteriaceae or lactobacilli during the study period in subjects consuming 0:10 sucrose:lactitol but there was a significant increase (P = 0.017) in bifidobacteria. There were no significant changes in faecal pH and SCFA for the 10:0 or 5:5 sucrose:lactitol groups but a significant decrease (P = 0.02) in faecal pH and significant increases (P = 0.001) in concentrations of propionic and butyric acids were observed in the 0:10 sucrose:lactitol group. There were few adverse symptoms of gastrointestinal intolerance to the daily consumption of 10 g lactitol.
Conclusions: The results show that low doses of lactitol can beneficially affect the faecal flora without eliciting gross symptoms of intolerance and that lactitol can be classified as a prebiotic.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00394-007-0666-7 | DOI Listing |
BMJ Open
January 2025
Clinical Research Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Introduction: Medicine quality can be influenced by environmental factors. In low- and middle-income countries (LMICs) with tropical climates, storage facilities of medicines in healthcare settings and homes may be suboptimal. However, knowledge of the effects of temperature and other climatic and environmental factors on the quality of medicines is limited.
View Article and Find Full Text PDFBMJ Open
January 2025
IMA World Health, Kinshasa, Democratic Republic of the Congo.
Objectives: To understand the current state of maternal, newborn and child health (MNCH) among internally displaced persons (IDPs), returnees and host communities in remote counties of Jonglei state.
Design: Cross-sectional, randomly sampled, mixed-methods, population-based household study.
Setting: Ayod, Nyirol, Fangak and Pigi counties of Jonglei, South Sudan.
Lupus Sci Med
January 2025
Department of Medicine, Dvision of Rheumatology, NYU Grossman School of Medicine, New York City, New York, USA.
Objective: Traditional initial treatment regimens for lupus nephritis (LN) used oral glucocorticoids (GC) in starting doses up to 1.0 mg/kg/day prednisone equivalent with or without a preceding intravenous methylprednisolone pulse. More recent management guidelines recommend lower starting oral GC doses following intravenous pulse therapy.
View Article and Find Full Text PDFJ Am Anim Hosp Assoc
January 2025
From Neuro Vets Animal Neurology Clinic, Kyoto, Kyoto, Japan (K.H., Y.N., M.N.).
A 5 yr old chihuahua presented to our clinic with a complaint of decreased activity and focal seizures. Based on the findings of MRI and computed tomography, a primary brain tumor originating from the right frontal lobe region was suspected. Surgical resection was performed, and a diagnosis of histiocytic sarcoma was made via histopathological examination and immunohistochemical staining.
View Article and Find Full Text PDFJ Crohns Colitis
January 2025
Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium and Department of Gastroenterology and Hepatology, University Hospitals Leuven, Belgium.
Background And Aims: Radiological imaging is crucial for diagnosing and monitoring patients with inflammatory bowel diseases (IBD). With increasing awareness of radiation risks, imaging doses should be 'as low as reasonably achievable', with a risk level that one should try to stay underneath 75 mSv. However, real-world data on cumulative exposure are limited.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!